Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00244621 · ClinicalTrials.gov registry record · Phase 3

Atacand Dose Ranging in Hypertensive Pediatric Subjects 1 Year to Less Than 6 Years of Age

A Phase 3 study of Hypertension, sponsored by AstraZeneca.

Completed
Registry status
Phase 3
Development phase
95
Enrollment target
20
Study locations

NCT00244621 is a Phase 3 study of Hypertension that has completed, run by AstraZeneca. The registered enrollment target is 95 participants, below the 3,507-participant average among 470 other Hypertension trials with a reported enrollment target (97% lower). The trial reports 20 study locations across 13 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00244621, a Phase 3 study of Hypertension, has completed, sponsored by AstraZeneca.

COMPLETED
Registry status
Phase 3
Development phase
95 participants
Enrollment target
20
Study locations

Study Summary

This is a dose ranging study of candesartan cilexetil in hypertensive pediatric subjects ages 1 to less than 6 years of age. It employs a double blind, randomized, dose ranging design intended for conduct as a multicenter trial. There are 3 study 'periods': a 1-week placebo run-in, a 4-week double blind treatment, and a 52-week open-label, long-term treatment period. Subjects undergo a screening evaluation, then a 1-week single-blind, placebo run-in, after which eligible subjects are allocated to receive 1 of 3 dose levels of candesartan cilexetil (0.05 mg/kg, or 0.20 mg /kg or 0.40 mg /kg), liquid formulation, in a 1:1:1 ratio for 4-weeks. At the end of randomized dose allocation (Day 28), blood pressure assessment will be performed and subjects may begin the 52-week, open-label treatment period of the study.

Conditions Studied

Hypertension

Interventions

  • DRUG candesartan cilexetil (Atacand)

Study Locations (20)

Other

  • Research Site - Edegem
  • Research Site - Ghent
  • Research Site - Aarhus
  • Research Site - Strasbourg

Texas

  • Research Site - Beaumont
  • Research Site - Houston
  • Research Site - San Antonio

California

  • Research Site - Los Angeles
  • Research Site - San Francisco

Florida

  • Research Site - Miami
  • Research Site - Orlando

Alabama

  • Research Site - Birmingham

Arkansas

  • Research Site - Little Rock

Idaho

  • Research Site - Boise

Michigan

  • Research Site - Detroit

Trial Details

FieldValue
Enrollment Target 95 participants
Start Date 2004-11
Est. Completion 2008-08
Phase Phase 3

Sponsor

AstraZeneca

1,285 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00244621

The ClinicalTrials.gov registry entry for NCT00244621 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 95 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 3,507-participant average among 470 other Hypertension trials with a reported enrollment target (97% lower). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Hypertension appearing as the primary indexed condition, and to 1 intervention - of which candesartan cilexetil (Atacand) is the first listed.

NCT00244621 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Other, Texas, California.

Frequently Asked Questions

What is clinical trial NCT00244621 about?

NCT00244621 is a clinical study titled "Atacand Dose Ranging in Hypertensive Pediatric Subjects 1 Year to Less Than 6 Years of Age". This is a dose ranging study of candesartan cilexetil in hypertensive pediatric subjects ages 1 to less than 6 years of age. It employs a double blind, randomized, dose ranging design intended for conduct as a multicenter trial. There are 3 study 'periods': a 1-week placebo run-in, a 4-week double b...

What is the current status of trial NCT00244621?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 95 participants. The study started on 2004-11. Estimated completion is 2008-08.

What conditions does trial NCT00244621 study?

This clinical trial studies the following conditions: Hypertension.

What interventions are being tested in trial NCT00244621?

The interventions under investigation include: candesartan cilexetil (Atacand) (DRUG).

Who is sponsoring clinical trial NCT00244621?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00244621 being conducted?

This trial has 20 study locations across Alabama, Arkansas, California, Florida, Idaho. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Hypertension

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Hypertension

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.